版本:
中国

BRIEF-Crispr Therapeutics signs service agreement with Masthercell SA

June 6 Crispr Therapeutics Ag:

* Crispr Therapeutics and Masthercell SA sign service agreement for the development and manufacturing of allogeneic cell therapies

* Crispr Therapeutics AG says masthercell will be responsible for development and CGMP manufacturing of CTX101 for use in clinical studies

* CTX101 is an allogeneic car T-cell therapy currently in development by Crispr therapeutics for treatment of CD19 positive malignancies Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐